MAIN CONTENT
A medical gain that does not yet balance the bill
The most striking figure in the CVS assessment is not a drug price but the gap between two different kinds of spending. Over three years, lower spending on hospital and other medical services saved participating health plans an estimated $9,400 per person. Additional prescription expenses reached $13,300, however, producing a net cost increase of $3,900. Savings in one part of the system therefore did not erase expenses in another.
The analysis used Aetna claims from people beginning GLP-1 treatment between 2023 and 2025 for obesity, diabetes and other conditions. Researchers compared them with similar nonusers, examining about 60,000 patients in the first year, 20,000 in the second and 4,000 who were still taking the medicines after three years. These changing sample sizes matter: later results concern a smaller, continuing-treatment group rather than everyone who initially received a prescription.
CVS associated treatment with 10% to 12% fewer emergency-room visits during the first two years and 34% to 42% fewer hospitalizations in the three-year continuing-user analysis. Such claims-based comparisons can reveal meaningful patterns, but they do not by themselves prove that medication alone caused every difference. The company also did not publish an obesity-only cost breakdown in the Reuters account, limiting how directly its overall finding can be applied to that specific population.

















